Deal includes up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earn out payments on net sales to Brickell
Read more at globenewswire.comBrickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here